Citation | Zehnder, L; Bennett, M; Meng, J; Huang, B; Ninkovic, S; Wang, F; Braganza, J; Tatlock, J; Jewell, T; Zhou, JZ; Burke, B; Wang, J; Maegley, K; Mehta, PP; Yin, MJ; Gajiwala, KS; Hickey, MJ; Yamazaki, S; Smith, E; Kang, P; Sistla, A; Dovalsantos, E; Gehring, MR; Kania, R; Wythes, M; Kung, PP Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyr J Med Chem54:3368-85 (2011) [PubMed] Article |
---|
SMILES | Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2CN(Cc12)C(=O)NCC(F)(F)F |(16.66,-44.44,;18,-43.67,;19.33,-44.44,;20.66,-43.67,;22,-44.43,;20.66,-42.12,;19.32,-41.36,;19.32,-39.82,;20.65,-39.04,;21.98,-39.81,;23.31,-39.03,;24.72,-39.65,;25.75,-38.5,;27.28,-38.65,;24.97,-37.17,;23.47,-37.5,;18,-42.13,;16.67,-41.36,;15.33,-42.14,;14,-41.37,;12.67,-42.13,;14,-39.82,;15.33,-39.05,;15.64,-37.55,;17.17,-37.38,;17.8,-38.78,;16.66,-39.81,;17.94,-36.04,;17.16,-34.71,;19.48,-36.04,;20.24,-34.7,;21.78,-34.69,;22.54,-33.36,;22.55,-36.02,;23.32,-34.69,)| |